4.4 Review

Ghrelin and motilin receptor agonists: time to introduce bias into drug design

期刊

NEUROGASTROENTEROLOGY AND MOTILITY
卷 26, 期 2, 页码 149-155

出版社

WILEY
DOI: 10.1111/nmo.12300

关键词

camicinal; GSK962040; constipation; gastroparesis; ghrelin; motilin; ulimorelin

资金

  1. AgeUK
  2. Tioga Pharmaceuticals
  3. Bowel and Cancer Research Charity
  4. Medical Research Council [G0900805] Funding Source: researchfish
  5. MRC [G0900805] Funding Source: UKRI

向作者/读者索取更多资源

Ghrelin and motilin receptor agonists increase gastric motility and are attractive drug targets. However, 14years after the receptors were described (18-24years since ligands became available) the inactivity of the ghrelin agonist TZP-102 in patients with gastroparesis joins the list of unsuccessful motilin agonists. Fundamental questions must be asked. Pustovit etal., have now shown that the ghrelin agonist ulimorelin evokes prolonged increases in rat colorectal propulsion yet responses to other ghrelin agonists fade. Similarly, different motilin agonists induce short- or long-lasting effects in a cell-dependent manner. Together, these and other data create the hypothesis that the receptors can be induced to preferentially signal (biased agonism') via particular pathways to evoke different responses with therapeutic advantages/disadvantages. Biased agonism has been demonstrated for ghrelin. Are motilin agonists which cause long-lasting facilitation of human stomach cholinergic function (compared with motilin) biased agonists (e.g., camicinal, under development for patients with gastric hypo-motility)? For ghrelin, additional complications exist because the therapeutic aims/mechanisms of action are uncertain, making it difficult to select the best (biased) agonist. Will ghrelin agonists be useful treatments of nausea and/or as suggested by Pustovit etal., chronic constipation? How does ghrelin increase gastric motility? As gastroparesis symptoms poorly correlate with delayed gastric emptying (yet gastro-prokinetic drugs can provide relief: e.g., low-dose erythromycin), would low doses of ghrelin and motilin agonists relieve symptoms simply by restoring neuromuscular rhythm? These questions on design and functions need addressing if ghrelin and motilin agonists are to reach patients as drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据